Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Pennsylvania

CNS medication trials in Pennsylvania

77 CNS medication studies are recruiting participants at sites in 12 cities across Pennsylvania as of November 17, 2026, according to ClinicalTrials.gov.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Pennsylvania city with a recruiting study

By research area: Depression (20), Parkinson's Disease (20), Migraine (10), Epilepsy (9), Schizophrenia (9), ADHD (4), Multiple Sclerosis (4), Bipolar Disorder (1).

Philadelphia (59), Pittsburgh (16), Allentown (5), Scottdale (4), Smithfield (4), Bethlehem (2), Hershey (2), West Chester (2), Willow Grove (2), Abington (1), Lancaster (1), Media (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Depression: recently updated in Pennsylvania

Basic details from each study's public record (the 12 most recently updated of 77). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Recruiting in
    Philadelphia
    Registry record
    NCT06793397 · updated
  2. Precision Depression Adalimumab Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Daniel Moriarity
    Recruiting in
    Philadelphia
    Registry record
    NCT07845604 · updated
  3. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Recruiting in
    Philadelphia
    Registry record
    NCT07002034 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Pennsylvania on ClinicalTrials.gov.

Parkinson's disease: recently updated in Pennsylvania

  1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Bethlehem
    Registry record
    NCT06623422 · updated
  2. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Bethlehem · Philadelphia · Pittsburgh
    Registry record
    NCT06952504 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Philadelphia · Willow Grove
    Registry record
    NCT07216703 · updated
  4. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Recruiting in
    Philadelphia · Pittsburgh
    Registry record
    NCT06989112 · updated
  5. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Pittsburgh
    Registry record
    NCT06469944 · updated
  6. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Lancaster
    Registry record
    NCT06345729 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Pennsylvania on ClinicalTrials.gov.

Multiple sclerosis (MS): recently updated in Pennsylvania

  1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Pittsburgh
    Registry record
    NCT03816345 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Pennsylvania on ClinicalTrials.gov.

Epilepsy: recently updated in Pennsylvania

  1. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Recruiting in
    Philadelphia
    Registry record
    NCT07563881 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Pennsylvania on ClinicalTrials.gov.

Migraine: recently updated in Pennsylvania

  1. Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

    • Phase 4
    • Ages 18 to 70
    • All sexes
    Sponsor
    Mayo Clinic
    Recruiting in
    Philadelphia
    Registry record
    NCT06972056 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Pennsylvania on ClinicalTrials.gov.

Ask about studies in Pennsylvania

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call